Eupraxia Pharmaceuticals Inc. Common Stock - Asset Resilience Ratio
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has an Asset Resilience Ratio of 34.39% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EPRX total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Eupraxia Pharmaceuticals Inc. Common Stock's Asset Resilience Ratio has changed over time. See what is Eupraxia Pharmaceuticals Inc. Common Sto's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Eupraxia Pharmaceuticals Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Eupraxia Pharmaceuticals Inc. Common Sto.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.59 Million | 34.39% |
| Total Liquid Assets | $8.59 Million | 34.39% |
Asset Resilience Insights
- Very High Liquidity: Eupraxia Pharmaceuticals Inc. Common Stock maintains exceptional liquid asset reserves at 34.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Eupraxia Pharmaceuticals Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Eupraxia Pharmaceuticals Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Eupraxia Pharmaceuticals Inc. Common Stock (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Eupraxia Pharmaceuticals Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -30.41% | $-6.16 Million | $20.27 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $25.89 Million | -- |
| 2021-12-31 | 28.85% | $9.01 Million | $31.22 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $1.45 Million | -- |
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more